Assessing the effects of exposure to a SARS-CoV-2 re-positive patient in healthcare personnel.

Yoshihiko Ogawa, Koji Nishida, Iwao Gohma, Kei Kasahara, Hisakazu Yano
Author Information
  1. Yoshihiko Ogawa: Department of Infectious Diseases, Sakai City Medical Center, Ebaraji 1-1-1, Sakai, Osaka, Japan. hikoichi.ogw@gmail.com. ORCID
  2. Koji Nishida: Treatment Team for COVID-19, Sakai City Medical Center, Ebaraji 1-1-1, Sakai, Osaka, Japan.
  3. Iwao Gohma: Treatment Team for COVID-19, Sakai City Medical Center, Ebaraji 1-1-1, Sakai, Osaka, Japan.
  4. Kei Kasahara: Center for Infectious Diseases, Nara Medical University, Shijo-cho 840, Kashihara, Nara, Japan.
  5. Hisakazu Yano: Department of Microbiology and Infectious Diseases, Nara Medical University, Shijo-cho 840, Kashihara, Nara, Japan.

Abstract

OBJECTIVE: To evaluate whether patients with COVID-19 who have tested re-positive with the PCR test for the SARS-CoV-2 virus are infectious is a challenge in the current circumstances. A follow-up survey was conducted with healthcare personnel (HCP) who were exposed to a patient whose PCR test results for SARS-CoV-2 were re-positive 18 days after the initial confirmation of negative PCR results.
RESULTS: We studied a total of 15 HCP who had contact exposures (15/15) and aerosol exposures (7/15). None of them tested positive for IgG against SARS-CoV-2 on blood examination. None of them had any symptoms during 10 days of active isolation. All PCR tests conducted using the nasopharyngeal swabs collected from the HCP on day 10 were negative. No apparent infection was found in any of the HCP who had contact exposure with and/or aerosol exposure to the patient whose PCR test results for SARS-CoV-2 were re-positive 18 days after the initial confirmation of negative results of PCR tests for SARS-CoV-2.
CLINICAL TRIAL: Trial Registration: No. 170, approved June 10th, 2020 by the ethics committee of Sakai City Medical Center.

Keywords

References

  1. Sci Rep. 2020 Jul 17;10(1):11887 [PMID: 32681141]
  2. EBioMedicine. 2020 Sep;59:102960 [PMID: 32853988]
  3. Disaster Med Public Health Prep. 2020 May 22;:1-3 [PMID: 32438941]
  4. Nature. 2020 May;581(7809):465-469 [PMID: 32235945]
  5. J Infect. 2020 May;80(5):e14-e17 [PMID: 32171867]
  6. N Engl J Med. 2020 Apr 16;382(16):1564-1567 [PMID: 32182409]
  7. Clin Infect Dis. 2020 Apr 08;: [PMID: 32266381]
  8. Clin Infect Dis. 2020 Aug 25;: [PMID: 33029620]

MeSH Term

Adult
Antibodies, Viral
Betacoronavirus
COVID-19
Coronavirus Infections
Female
Humans
Immunoglobulin G
Infectious Disease Transmission, Patient-to-Professional
Male
Middle Aged
Pandemics
Pneumonia, Viral
Polymerase Chain Reaction
SARS-CoV-2
Young Adult

Chemicals

Antibodies, Viral
Immunoglobulin G

Word Cloud

Created with Highcharts 10.0.0PCRSARS-CoV-2re-positiveHCPresultstestpersonnelpatientnegativeexposureCOVID-19testedconductedhealthcarewhose18 daysinitialconfirmationcontactexposuresaerosolNonetestsOBJECTIVE:evaluatewhetherpatientsvirusinfectiouschallengecurrentcircumstancesfollow-upsurveyexposedRESULTS:studiedtotal1515/157/15positiveIgGbloodexaminationsymptoms10 daysactiveisolationusingnasopharyngealswabscollectedday10apparentinfectionfoundand/orCLINICALTRIAL:TrialRegistration:170approvedJune10th2020ethicscommitteeSakaiCityMedicalCenterAssessingeffectsHealthcare

Similar Articles

Cited By